2024-10-18 - Analysis Report
## Amgen Inc (AMGN) Stock Analysis

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets a range of human therapeutics.

**1. Performance Comparison with S&P 500 (VOO):**

* **Cumulative Return:** AMGN has a cumulative return of 79.87% while the S&P 500 (VOO) has a return of 136.93%.
* **Relative Divergence:** AMGN is currently lagging behind VOO by -57.06%, which represents 29.04% of the historical range of divergence (max: 7.29, min: -79.13). 

**2. Recent Price Action:**

* **Closing Price:** $321.63
* **5-Day Moving Average:** $324.14
* **20-Day Moving Average:** $323.98
* **60-Day Moving Average:** $326.99

**3. Technical Indicators:**

* **RSI:** 52.84 (Neutral)
* **PPO:** 0.11 (Slight Bullish)
* **Delta_Previous_Relative_Divergence:** -14.28 (Short-term bearish)
* **Expected Return:** 0.0% (Maximum 5-year expected return over S&P 500, VOO)

**4. Recent Earnings and Outlook:**

* **Earnings:**
| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |
* **Most Recent Earnings:** The most recent earnings for Q2 2024 (released on Aug 7th, 2024) showed EPS of 1.39, beating analyst estimates of 1.34. Revenue came in at $8.39B, surpassing the estimated $8.31B.

**5. News and Recent Issues:**

* **Recent Market Outlook:** The market outlook for AMGN remains mixed. Analysts are closely watching the ongoing development of new drugs and the impact of competition from biosimilars. 
* **Analyst Opinions and Performance Highlights:** According to FINBOLD, the average analyst price target for AMGN is $342.56, suggesting potential upside. However, the recent decline in the stock price has raised some concerns among investors.  

**6. Overall Analysis:**

AMGN is a leading biotechnology company with a solid track record. While its stock price has lagged behind the S&P 500 in recent months, its strong earnings performance and pipeline of new drugs suggests future potential. The stock is currently trading near its 50-day moving average, and technical indicators are mixed. 

**7. Conclusion:**

Overall, AMGN remains a solid investment for long-term investors, although it may be prudent to wait for the stock to consolidate further before considering a purchase. 

**Disclaimer:** This analysis is for informational purposes only and does not constitute financial advice. It is crucial to conduct thorough research and consult with a financial professional before making any investment decisions.